Pipeline

Product

Indication

Single agent/ Combination

Preclinical

Phase I

Phase II

Phase III / Pivotal

Filed

Approved

Cosibelimab

Anti-PD-L1 Antibody

cSCC

Metastatic

Single Agent

cSCC

Locally
Advanced

Single Agent

Olafertinib

3rd Generation EGFR Inhibitor

NSCLC

EGFR mut+

Cosibelimab +
Olafertinib

Earlier Stage Programs

Earlier Stage Programs

CK-103

CK-302

CK-303

BET Inhibitor

Solid Tumor

Anti-GITR

Solid Tumor

Anti-CAIX

Solid Tumor